These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 16926632)

  • 1. Kinamycins A and C, bacterial metabolites that contain an unusual diazo group, as potential new anticancer agents: antiproliferative and cell cycle effects.
    Hasinoff BB; Wu X; Yalowich JC; Goodfellow V; Laufer RS; Adedayo O; Dmitrienko GI
    Anticancer Drugs; 2006 Aug; 17(7):825-37. PubMed ID: 16926632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors.
    Liang H; Wu X; Yalowich JC; Hasinoff BB
    Mol Pharmacol; 2008 Mar; 73(3):686-96. PubMed ID: 18045852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvicine functions as novel topoisomerase II poison by binding to ATP pocket.
    Hu CX; Zuo ZL; Xiong B; Ma JG; Geng MY; Lin LP; Jiang HL; Ding J
    Mol Pharmacol; 2006 Nov; 70(5):1593-601. PubMed ID: 16914642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical and proteomics approaches to characterize topoisomerase IIalpha cysteines and DNA as targets responsible for cisplatin-induced inhibition of topoisomerase IIalpha.
    Hasinoff BB; Wu X; Krokhin OV; Ens W; Standing KG; Nitiss JL; Sivaram T; Giorgianni A; Yang S; Jiang Y; Yalowich JC
    Mol Pharmacol; 2005 Mar; 67(3):937-47. PubMed ID: 15602006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A series of alpha-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase IIalpha catalytic activity.
    Huang H; Chen Q; Ku X; Meng L; Lin L; Wang X; Zhu C; Wang Y; Chen Z; Li M; Jiang H; Chen K; Ding J; Liu H
    J Med Chem; 2010 Apr; 53(8):3048-64. PubMed ID: 20353152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs.
    Jensen LH; Liang H; Shoemaker R; Grauslund M; Sehested M; Hasinoff BB
    Mol Pharmacol; 2006 Nov; 70(5):1503-13. PubMed ID: 16880287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thiol-modulated mechanisms of the cytotoxicity of thimerosal and inhibition of DNA topoisomerase II alpha.
    Wu X; Liang H; O'Hara KA; Yalowich JC; Hasinoff BB
    Chem Res Toxicol; 2008 Feb; 21(2):483-93. PubMed ID: 18197631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinamycin F downregulates cyclin D3 in human leukemia K562 cells.
    O'Hara KA; Dmitrienko GI; Hasinoff BB
    Chem Biol Interact; 2010 Mar; 184(3):396-402. PubMed ID: 20079721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel antitumor indenoindole derivatives targeting DNA and topoisomerase II.
    Bal C; Baldeyrou B; Moz F; Lansiaux A; Colson P; Kraus-Berthier L; Léonce S; Pierré A; Boussard MF; Rousseau A; Wierzbicki M; Bailly C
    Biochem Pharmacol; 2004 Nov; 68(10):1911-22. PubMed ID: 15476662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-regulation of DNA topoisomerase IIalpha leads to prolonged cell cycle transit in G2 and early M phases and increased survival to microtubule-interacting agents.
    Skladanowski A; Côme MG; Sabisz M; Escargueil AE; Larsen AK
    Mol Pharmacol; 2005 Sep; 68(3):625-34. PubMed ID: 15942022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase IIα and induce apoptosis in G1/S phase.
    Baviskar AT; Madaan C; Preet R; Mohapatra P; Jain V; Agarwal A; Guchhait SK; Kundu CN; Banerjee UC; Bharatam PV
    J Med Chem; 2011 Jul; 54(14):5013-30. PubMed ID: 21644529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity studies with cytotoxic anthrapyrazoles.
    Begleiter A; Lin D; Larson KK; Lang J; Wu X; Cabral T; Taylor H; Guziec LJ; Kerr PD; Hasinoff BB; Guziec FS
    Oncol Rep; 2006 Jun; 15(6):1575-80. PubMed ID: 16685398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico studies with human DNA topoisomerase-II alpha to unravel the mechanism of in vitro genotoxicity of benzene and its metabolites.
    Pandey AK; Gurbani D; Bajpayee M; Parmar D; Ajmani S; Dhawan A
    Mutat Res; 2009 Feb; 661(1-2):57-70. PubMed ID: 19059273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topoisomerase II beta levels are a determinant of melphalan-induced DNA crosslinks and sensitivity to cell death.
    Emmons M; Boulware D; Sullivan DM; Hazlehurst LA
    Biochem Pharmacol; 2006 Jun; 72(1):11-8. PubMed ID: 16678798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The anticancer thiosemicarbazones Dp44mT and triapine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase IIα.
    Yalowich JC; Wu X; Zhang R; Kanagasabai R; Hornbaker M; Hasinoff BB
    Biochem Pharmacol; 2012 Jul; 84(1):52-8. PubMed ID: 22503743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lycobetaine acts as a selective topoisomerase II beta poison and inhibits the growth of human tumour cells.
    Barthelmes HU; Niederberger E; Roth T; Schulte K; Tang WC; Boege F; Fiebig HH; Eisenbrand G; Marko D
    Br J Cancer; 2001 Nov; 85(10):1585-91. PubMed ID: 11720449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase II.
    Hasinoff BB; Wu X; Begleiter A; Guziec LJ; Guziec F; Giorgianni A; Yang S; Jiang Y; Yalowich JC
    Cancer Chemother Pharmacol; 2006 Jan; 57(2):221-33. PubMed ID: 16010589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of the cytotoxicity of the diazoparaquinone antitumor antibiotic kinamycin F.
    O'Hara KA; Wu X; Patel D; Liang H; Yalowich JC; Chen N; Goodfellow V; Adedayo O; Dmitrienko GI; Hasinoff BB
    Free Radic Biol Med; 2007 Oct; 43(8):1132-44. PubMed ID: 17854709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and characterization of the biological activity of the cisplatin analogs, cis-PtCl(2)(dexrazoxane) and cis-PtCl(2)(levrazoxane), of the topoisomerase II inhibitors dexrazoxane (ICRF-187) and levrazoxane (ICRF-186).
    Hasinoff BB; Wu X; Yang Y
    J Inorg Biochem; 2004 Apr; 98(4):616-24. PubMed ID: 15041241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors.
    Jensen LH; Thougaard AV; Grauslund M; Søkilde B; Carstensen EV; Dvinge HK; Scudiero DA; Jensen PB; Shoemaker RH; Sehested M
    Cancer Res; 2005 Aug; 65(16):7470-7. PubMed ID: 16103101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.